List of phase III cancer clinical trials, 2016

Phase III Clinical Trials by Year

compound	cancer type	reference	companies involved
ribociclib	breast cancer	^[1]	Novartis, Astex Pharmaceuticals
bavituximab	non-small cell lung cancer		Peregrine Pharmaceuticals
Palbociclib	breast cancer		Pfizer
brigatinib	lung cancer		ARIAD Pharmaceuticals
binimetinib	ovarian cancer		Array Biopharma
encorafenib	melanoma		Array Biopharma
bevacizumab	ovarian cancer		Genentech
alectinib	lung cancer		Chugai Pharmaceutical Co.
eribulin	breast cancer		Eisai Co.
duvelisib	blood cancers
degarelix	prostate cancer		Ferring Pharmaceuticals
neratinib	breast cancer		Puma Biotechnology
nilotinib	chronic myeloid leukemia		Novartis
sorafenib	thyroid cancer		Bayer, Onyx Pharmaceuticals
enzalutamide	prostate cancer		Medivation
Durvalumab/Tremelimumab	breast cancer
sacituzumab govitecan	breast cancer
cabozantinib	hepatocellular carcinoma		Exelixis
Binimetinib	melanoma		QIAGen, Array Biopharma
Nivolumab	neck cancer		Bristol-Myers Squibb
Panitumumab	colorectal cancer		Amgen

References[edit]

This article "List of phase III cancer clinical trials, 2016" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:List of phase III cancer clinical trials, 2016. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.